Clinical trial of indomethacin in alzheimer’s disease

J. Rogers, L. C. Kirby, S. R. Hempelman, D. L. Berry, P. L. McGeer, A. W. Kaszniak, J. Zalinski, M. Cofield, L. Mansukhani, P. Willson, F. Kogan

Research output: Contribution to journalArticlepeer-review

965 Scopus citations


In a 6-month, double-blind, placebo-controlled study, 1100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer’s disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (±1.8%), whereas placebo patients declined 8.4% (±2.3%)—a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.

Original languageEnglish (US)
Pages (from-to)1609-1611
Number of pages3
Issue number8
StatePublished - Aug 1993

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Clinical trial of indomethacin in alzheimer’s disease'. Together they form a unique fingerprint.

Cite this